Dr. Donato Perez GarcíaHospital Ángeles Tijuana
USA 619 798 8017
MEX 52 +664 635 1827
Insulin Potentiation Therapy (IPT®) is a medical protocol in which the hormone insulin is used as a pharmacologic adjunct to potentiate the effects of commonly used allopathic medications.
Insulin Potentiation Therapy Low Dose (IPTLD ®) manipulates the mechanisms of malignancy to therapeutic advantage by employing insulin as a biologic response modifier of cancer cells endogenous molecular biology. The autonomous proliferation of malignancy is supported by autocrine secretion of insulin for glucose/energy uptake by cancer cells, and a similar autocrine and/or paracrine elaboration of cellular factors to stimulate cancer growth. Amongst these, the insulin-like growth factors have been identified as the most potent mitogens for cancer cells.
Of primary importance for IPTLD ®, cancer cell membranes also have six times more insulin receptors and ten times more IGF receptors, per cell, than the membranes of host normal tissues. Further, insulin can cross-react with and activate cancer cell IGF receptors. Thus, per cell, cancer has sixteen times more insulin-sensitive receptors than normal tissues. As ligand effect is a function of receptor concentration, these facts serve to differentiate cancer from normal cells – a vital consideration for the safety of cancer chemotherapy. In light of these revelations, exogenous insulin acts to enhance anticancer drug cytotoxicity, and safety, via:
1) A membrane permeability effect to increase the intracellular dose intensity of the drugs;
2) An effect of metabolic modification to increase the S-phase fraction in cancer cells, enhancing their susceptibility to cell-cycle phase-specific agents, and;
3) an effect of biochemical differentiation based on insulin receptor concentration that focuses the first two insulin effects predominantly on cancer cells, sparing host normal tissues.